Dupilumab Improves Health-related Quality of Life and Asthma Control in Patients With and Without Coexisting Type 2 Conditions: Results from the RAPID Study
Bibliographic record
Abstract
Abstract RATIONALE: Asthma frequently coexists with other type 2 inflammatory diseases such as chronic rhinosinusitis (CRS) and nasal polyposis (NP), resulting in poor asthma control and impaired quality of life. Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, key and central drivers of type 2 inflammation, demonstrated efficacy in multiple clinical trials of patients with asthma; however, few studies provide evidence for its real-world effectiveness. RAPID (NCT04287621) is a global, prospective, observational registry of patients initiating dupilumab for asthma as primary indication in a real-world setting. This analysis characterized patient-reported outcomes in patients from the RAPID registry with and without a history of coexisting CRS and/or NP. METHODS: RAPID enrolled patients aged ≥12 years with moderate-to severe uncontrolled asthma initiating dupilumab for asthma according to country-specific prescribing information. We assessed unadjusted annualized rate of severe exacerbation events at Month 12 and change from baseline throughout the 12-month study period in scores from the Sino-Nasal Outcome Test-22 (SNOT-22; scores range from 0 to 110, with higher scores indicating more severe symptoms and greater CRS impact) and the 6-item Asthma Control Questionnaire (ACQ-6; scores range from 0 to 6, with higher scores indicating more severe symptoms). Outcomes were stratified by the presence of coexisting CRS and/or NP. RESULTS: 205 patients were analyzed (94 with ongoing CRS and/or NP; 111 without ongoing CRS and/or NP). At Week 52, the unadjusted annualized rates of severe exacerbations were similar in patients with and without ongoing CRS and/or NP (0.146 vs 0.129). Dupilumab reduced SNOT-22 scores in patients with ongoing CRS and/or NP, with mean (standard deviation [SD]) reductions of −15.2 (21.3), −19.8 (20.7), and −17.0 (26.2) points at Months 1, 6, and 12, respectively (Table). Dupilumab reduced mean (SD) ACQ-6 scores by −0.9 (1.2), −1.1 (1.1), −1.2 (1.2), −1.3 (1.2), and −1.3 (1.1) points at Months 1, 3, 6, 9, and 12, respectively, in patients with ongoing CRS and/or NP (Table). In patients without ongoing CRS and/or NP, ACQ-6 scores were reduced by −1.1 (1.1), −1.3 (1.1), −1.3 (1.3), −1.2 (1.1), and −1.4 (1.1) points at Months 1, 3, 6, 9, and 12, respectively (Table). CONCLUSION: In this analysis of RAPID, dupilumab improved symptomatic asthma control in patients with moderate-to-severe uncontrolled asthma, irrespective of the presence of coexisting CRS and/or NP, and also improved CRS symptoms in patients with CRS and/or NP.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.003 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.003 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".